Association of body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) who received targeted therapies (TT).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 3592-3592
Author(s):  
Gargi Surendra Patel ◽  
Shahid Ullah ◽  
Carol Beeke ◽  
Paul Hakendorf ◽  
Rob Padbury ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Body Mass Index ◽  
Overall Survival ◽  
Clinical Characteristics ◽  
Independent Predictor ◽  
Retrospective Data ◽  
Insulin Dependent ◽  
Baseline Characteristics ◽  
Metastatic Sites ◽  
The Relationship

3592 Background: Preclinical data suggest that adiposity activates pro-inflammatory and insulin-dependent pathways which may lead to resistance to TT, e.g., bevacizumab (Bev) or cetuximab (Cet). Only two retrospective trials have studied the relationship between BMI and outcome for mCRC pts who received TT, with conflicting results. Our aim was to compare OS across BMI groups for mCRC pts treated with TT. Methods: Retrospective data, pertaining to clinical characteristics and outcome, were obtained from the South Australian Registry for mCRC from Feb 2006-Oct 2012. The BMI at first treatment was grouped as Normal (N) = 18.5- <25, Overweight (OW) = 25- <30, Obese I(Ob1) = 30- <35, Obese II (Ob2)≥35. Results: Of 1,174 pts, 39% were OW, 15% Ob1 and 7% Ob2. 352 pts received chemo+TT (Bev, Cet, panitumumab (Pan) and/or regorafenib) and 814 chemo alone. Baseline characteristics were similar across all BMI groups except for type of mCRC: N pts were more likely than obese pts to have synchronous CRC (77.9% vs 56-69.7% for obese). On adjustment for age, sex, synchronous disease, metastatic sites, number of lines of chemo and TT, median OS was longer for N versus OW or Ob1 pts with chemo+TT (35.4 vs 24.9 or 22.7 mons, Table) with no difference in OS for chemo alone. Only N gp pts had an improvement in OS on the addition of TT to chemo. On breakdown by type of TT, OW and Ob1 pts had a poorer outcome with Bev but not with EGFR TT. Conclusions: The BMI is an independent predictor for a poorer outcome for OW and OB1 pts with chemo+TT, specifically for pts receiving Bev. The OW and OB1 patients may be a target group for lifestyle and nutrition advice to improve OS with TT. Prospective studies are required to validate this finding. [Table: see text]

Identification of a lncRNA prognostic signature-related to stem cell index and its significance in colorectal cancer

2021 ◽  
Author(s):  
Xiao-Cheng Wang ◽  
Ya Liu ◽  
Fei-Wu Long ◽  
Liang-Ren Liu ◽  
Chuan-Wen Fan
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Prognostic Markers ◽  
The Cancer Genome Atlas ◽  
Prognostic Signature ◽  
Free Survival ◽  
Cancer Genome Atlas ◽  
Bioinformatic Approaches ◽  
Cell Phenotypes ◽  
The Relationship

Background: The relationship between long noncoding RNAs (lncRNAs) and the mRNA stemness index (mRNAsi) in colorectal cancer (CRC) is still unclear. Materials & methods: The mRNAsi, mRNAsi-related lncRNAs and their clinical significance were analyzed by bioinformatic approaches in The Cancer Genome Atlas (TCGA)-COREAD dataset. Results: mRNAsi was negatively related to pathological features but positively related to overall survival and recurrence-free survival in CRC. A five mRNAsi-related lncRNAs prognostic signature was further developed and showed independent prognostic factors related to overall survival in CRC patients, due to the five mRNAsi-related lncRNAs involved in several pathways of the cancer stem cells and malignant cancer cell phenotypes. Conclusion: The present study highlights the potential roles of mRNAsi-related lncRNAs as alternative prognostic markers.

scholarly journals The Relationship Between Health-Related Quality of Life and Survival in Metastatic Colorectal Cancer Patients Treated With Korean Medicine

2016 ◽  
Vol 17 (1) ◽  
pp. 65-72 ◽  
Author(s):  
Sora Park ◽  
Wankyu Eo ◽  
Sookyung Lee
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Clinical Characteristics ◽  
Health Related Quality ◽  
Korean Medicine ◽  
Related Quality ◽  
Health Related ◽  
The Relationship

Objectives. This study aimed to identify the relationship between health-related quality of life (HRQoL) measured by the Functional Assessment Cancer Therapy–General (FACT-G) and survival in metastatic colorectal cancer (mCRC) patients. Methods. The clinical characteristics and FACT-G scores were retrospectively reviewed in mCRC patients who visited the Cancer Center of Korean Medicine. The overall survival (OS) was calculated and compared using the Kaplan-Meier method and log-rank test. Univariate and multivariate Cox regression analyses were performed based on clinical characteristics and FACT-G scores. To identify significant differences in answer frequency, χ2 tests and Fisher’s exact tests were used. Results. A total of 58 patients were reviewed. The proportion of patients who had an Eastern Cooperative Oncology Group–Performance Status ≥ 2 was 43.1%, multiple distant metastatic sites was 77.6%, liver metastases was 43.1%, been previously treated was 89.7%, and received more than the second-line chemotherapy was 75.5%. The mean total FACT-G score was 65.3 (median 65.6). The median OS was 7 months. There was no significant difference in OS between the 2 groups divided by the median values of FACT-G total and subscores. In univariate analyses, functional well-being (FWB) score had a significant impact on survival. In multivariate analyses, presence of liver metastasis, FACT-G total score, and FWB score were significant prognostic predictors of survival. No statistically different answer frequency was observed for any question regarding FWB. Conclusions. This study found that FACT-G total and FWB scores were potential prognostic factors for predicting OS in relapsed or refractory mCRC patients treated with Korean Medicine.

scholarly journals Percutaneous Cryoablation of Metastatic Lesions from Colorectal Cancer: Efficacy and Feasibility with Survival and Cost-Effectiveness Observations

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Hyun J. Bang ◽  
Peter J. Littrup ◽  
Brandt P. Currier ◽  
Dylan J. Goodrich ◽  
Minsig Choi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Cost Effectiveness ◽  
Local Recurrence ◽  
Major Complication ◽  
Cost Effective ◽  
Tumor Location ◽  
Recurrence Rates ◽  
Metastatic Sites ◽  
Systemic Therapies

Purpose. To assess feasibility, complications, local tumor recurrences, overall survival (OS) and estimates of cost-effectiveness for multi-site cryoablation (MCA) of oligo-metastatic colorectal cancer (mCRC) in a prospective study. Materials and Methods. 111 CT and/or US-guided percutaneous MCA procedures were performed on 151 tumors in 59 oligo mCRC patients. Mean patient age was 63 years (range 21–92 years), consisting of 29 males and 30 females. Tumor location was grouped according to common metastatic sites. Median OS was determined using the Kaplan-Meier. Estimates of MCA costs per LYG were compared to historical values for systemic therapies. Results. A mean 1.9 MCAs per patient were performed with a median clinical follow-up of 12 months. Major complication and local recurrence rates were 8% (9/111) and 12% (18/151), respectively. Median overall-survival (OS) was 23.6 months with an estimated 3-year survival rate of ~30%. Cryoablation remained cost effective with or without the presence of systemic therapies, with an adjunctive cost-effectiveness ratio (ACER) of $39,661–$85,580 per LYG. Conclusions. Multi-site cryoablation had very low complication and local recurrence rates, and was able to provide local control even for diverse soft tissue locations. Even as an adjunct to systemic therapies, MCA appeared cost-effective, with apparent increased survival.

scholarly journals The Relationship of Body Mass Index with Disease Activity in Ankylosing Spondylitis

2020 ◽  
Vol 3 (2) ◽  
pp. 71-85
Author(s):  
Raouf Merza ◽  
Kurdistan Ali ◽  
Dlair Mohamad ◽  
Sundus Wahhab
Keyword(s):  
Body Mass Index ◽  
Disease Activity ◽  
Body Mass ◽  
Clinical Characteristics ◽  
Disease Activity Score ◽  
Activity Score ◽  
P Value ◽  
Disease Characteristics ◽  
And Gender ◽  
The Relationship

Find out the relationship between body mass index (BMI) and W.C with disease activity scorein AS patients and its association with clinical characteristics of AS. One hundred and five patients (75 male and 30 female) who visited rheumatology and medical rehabilitation centerin Sulaimani city were recorded in this cross-sectional study. Disease activity was measured by ASDAS-ESR in the hand-held calculator.BMI was calculated and waist circumference(W.C.) was measured and both were evaluated with disease activity score and disease characteristics in those with normal BMI and W.C and those with abnormal BMI and W.C.Data of one hundred and five patients were involved in this study with a mean age of 37±9.5 years with the predominance of male gender (71.4%). The mean BMI of the patients was27.2±4.6 kg/m², 28.6% of them were obese and 35.2% of them were overweight. Patients who were overweight, obese and increased W.C had significantly higher disease activity scoresand older compared to those who had normal BMI and W.C(p value<0.05).There was no statistically significant difference between the two groups in terms of peripheral arthritis,disease duration, clinical characteristics of AS, and gender (P value>0.05). Overweight, obesity and increased W.C are common among AS patients and significantly related to disease activity score and age, but not with disease characteristics and gender

Chemotherapy dose reductions in obese patients undergoing adjuvant chemotherapy for colorectal cancer: secondary analyses of trial data and the Greater Manchester and Cheshire Cancer Network Audit.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 763-763
Author(s):  
Prakhar Srivastava ◽  
Lee Malcolmson ◽  
Mark P. Saunders ◽  
Andrew Renehan
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Adjuvant Chemotherapy ◽  
Stage Iv ◽  
Obese Patients ◽  
Cancer Specific Survival ◽  
Stage Iv Cancer ◽  
Cancer Network ◽  
The Relationship ◽  
Dose Reductions

763 Background: In patients with stage II/III colorectal cancer receiving adjuvant chemotherapy, doses are calculated using body surface area (BSA) but often capped at BSA > 2.0. Dose capping might be a mechanism of reported poorer survival in obese patients. We aimed to investigate the different dosing schedules across BMI categories, using trial and ‘real world’ audit datasets, and determine its impact upon overall survival. Methods: Data was accessed for 1122 patients from the control arm of the MOSAIC trial (accessed via the Data Project Sphere) and 327 patients from the Greater Manchester and Cheshire Cancer Network (GMCCN) audit. Pearson’s χ2 and correlation coefficient were used to assess the relationship between BMI (expressed as normal, overweight and obese: and as continuous, respectively) and dose reductions. A multiple logistic regression model was constructed to compare the odds of receiving dose reductions in each BMI category. 4-year overall survival was calculated for each BMI category and dose status. Results: In MOSAIC, there were increasing dose reductions by BMI category: normal, 3%; overweight, 5%; and obese, 11%, with similar patterns in the GMCCN OxMdG group. Obese patients in MOSAIC and the GMCCN OxMdG group had 3- and 12-fold higher odds (OR = 3.4 and 12.5, CI = 1.6-7.0 and 2.0-78.1), respectively, of receiving dose reductions. However, these differences did not translate to differences in overall survival by BMI category or dose status. Conclusions: In our investigated datasets, there appears to be a relationship between increasing BMI and dose reductions, though it is modest and does not manifest as a detrimental influence on overall survival. Our findings agreed with other studies performed using stage IV cancer patients, although the relationship between increasing BMI and dose reductions is more prominent in patients with metastatic disease. Investigating other outcome measures such as cancer-specific survival and chemotherapy related toxicity is required for clarity.

Sign in / Sign up

Export Citation Format

Share Document